Phathom Pharmaceuticals
Update in progressPHAT (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing gastrointestinal therapies in the United States. Its lead product, VOQUEZNA (vonoprazan), has completed Phase III trials for erosive GERD and related heartburn in adults, and for Helicobacter pylori regimens (Triple Pak and Dual Pak). VOQUEZNA is also studied for non-erosive GERD and eosinophilic esophagitis. Founded in 2018, it is based in Florham Park, New Jersey.
Company score
- Sentiment
- 0.42
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.17
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!